ATE391778T1 - Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen - Google Patents

Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen

Info

Publication number: ATE391778T1
Authority: AT; Austria
Prior art keywords: vegf; mutants; growth factor; vascular endothelial; endothelial cell
Prior art date: 1997-02-05

Application number

AT98904842T

Other languages

English (en)

Inventor

Kari Alitalo

Vladimir Joukov

Original Assignee

Ludwig Inst Cancer Res

Licentia Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-05

Filing date

1998-02-02

Publication date

2008-04-15

1998-02-02 Application filed by Ludwig Inst Cancer Res, Licentia Ltd filed Critical Ludwig Inst Cancer Res

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE391778T1 publication Critical patent/ATE391778T1/de

Links

230000003511 endothelial effect Effects 0.000 title 1
239000003102 growth factor Substances 0.000 title 1
230000002792 vascular Effects 0.000 title 1
102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 abstract 2
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 abstract 2
102000040430 polynucleotide Human genes 0.000 abstract 2
108091033319 polynucleotide Proteins 0.000 abstract 2
239000002157 polynucleotide Substances 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
102000027426 receptor tyrosine kinases Human genes 0.000 abstract 2
108091008598 receptor tyrosine kinases Proteins 0.000 abstract 2
101150009958 FLT4 gene Proteins 0.000 abstract 1
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
235000018417 cysteine Nutrition 0.000 abstract 1
238000012217 deletion Methods 0.000 abstract 1
230000037430 deletion Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT98904842T 1997-02-05 1998-02-02 Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen ATE391778T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/795,430 US6130071A (en)	1997-02-05	1997-02-05	Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof

Publications (1)

Publication Number	Publication Date
ATE391778T1 true ATE391778T1 (de)	2008-04-15

Family

ID=25165495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98904842T ATE391778T1 (de)	1997-02-05	1998-02-02	Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen

Country Status (7)

Country	Link
US (1)	US6130071A (de)
EP (1)	EP0972028B1 (de)
JP (1)	JP4524340B2 (de)
AT (1)	ATE391778T1 (de)
AU (1)	AU748369C (de)
CA (1)	CA2279554C (de)
DE (1)	DE69839340T2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6824777B1 (en) *	1992-10-09	2004-11-30	Licentia Ltd.	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7109308B1 (en) *	1994-03-08	2006-09-19	Human Genome Sciences, Inc.	Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) *	1994-03-08	2006-12-26	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 and methods of use
US5932540A (en)	1994-03-08	1999-08-03	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
ES2249762T3 (es)	1994-03-08	2006-04-01	Human Genome Sciences, Inc.	Factor de crecimiento del endotelio vascular 2.
US6608182B1 (en) *	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US6040157A (en) *	1994-03-08	2000-03-21	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US7186688B1 (en) *	1994-03-08	2007-03-06	Human Genome Sciences, Inc.	Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6645933B1 (en)	1995-08-01	2003-11-11	Helsinki University Licensing Ltd. Oy	Receptor ligand VEGF-C
EP1353952B1 (de)	1994-11-14	2007-04-11	Ludwig Institute For Cancer Research	Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
US6818220B1 (en)	1994-11-14	2004-11-16	Licentia Ltd.	Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) *	1995-08-01	2008-09-09	Vegenics Limited	Antibodies to VEGF-C
US6361946B1 (en)	1997-02-05	2002-03-26	Licentia Ltd	Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
DE69628652T3 (de) *	1995-09-08	2012-05-03	Genentech, Inc.	Vegf-verwandtes protein
US7125714B2 (en) *	1997-02-05	2006-10-24	Licentia Ltd.	Progenitor cell materials and methods
US7223724B1 (en) *	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
WO2000058511A1 (en) *	1999-03-26	2000-10-05	Ludwig Institute For Cancer Research	Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
US6764820B2 (en) *	1999-03-26	2004-07-20	Ludwig Institute For Cancer Research	Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
AU3988401A (en) *	2000-02-25	2001-09-03	Ludwig Inst Cancer Res	Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
MXPA02003434A (es) *	2000-08-04	2002-09-02	Human Genome Sciences Inc	Factor de crecimiento endotelial vascular 2.
US20040101825A1 (en) *	2001-09-26	2004-05-27	Van Meir Erwin G.	Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) *	2000-09-26	2007-10-23	Emory University	Viruses targeted to hypoxic cells and tissues
WO2002036131A1 (en) *	2000-11-01	2002-05-10	Ludwig Institute For Cancer Research	In vivo stimulation of angiogenic activity
AU2002228841C1 (en) *	2000-12-07	2006-11-23	Sangamo Biosciences, Inc	Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) *	2000-12-07	2006-06-27	Sangamo Biosciences, Inc.	Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) *	2001-01-17	2009-11-03	Vegenics Limited	VEGFR-3 inhibitor materials and methods
US7402312B2 (en) *	2001-04-13	2008-07-22	Human Genome Sciences, Inc.	Antibodies to vascular endothelial growth factor 2 (VEGF-2)
CA2444632A1 (en) *	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
AU2002252631A1 (en) *	2001-04-13	2002-10-28	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US20050232921A1 (en) *	2001-04-13	2005-10-20	Rosen Craig A	Vascular endothelial growth factor 2
WO2002083850A2 (en) *	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
WO2003006104A2 (en) *	2001-07-12	2003-01-23	Ludwig Institute For Cancer Research	Lymphatic endothelial cells materials and methods
US20030113324A1 (en)	2001-10-01	2003-06-19	Kari Alitalo	Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) *	2001-10-01	2004-10-28	Kari Alitalo	VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US7794693B2 (en)	2002-03-01	2010-09-14	Bracco International B.V.	Targeting vector-phospholipid conjugates
US8623822B2 (en)	2002-03-01	2014-01-07	Bracco Suisse Sa	KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7985402B2 (en) *	2002-03-01	2011-07-26	Bracco Suisse Sa	Targeting vector-phospholipid conjugates
US7261876B2 (en)	2002-03-01	2007-08-28	Bracco International Bv	Multivalent constructs for therapeutic and diagnostic applications
US20050250700A1 (en) *	2002-03-01	2005-11-10	Sato Aaron K	KDR and VEGF/KDR binding peptides
US20050100963A1 (en) *	2002-03-01	2005-05-12	Dyax Corporation	KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7666979B2 (en) *	2002-03-01	2010-02-23	Bracco International B.V.	Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7211240B2 (en)	2002-03-01	2007-05-01	Bracco International B.V.	Multivalent constructs for therapeutic and diagnostic applications
US20030232437A1 (en) *	2002-06-17	2003-12-18	Isis Pharmaceuticals Inc.	Antisense modulation of VEGF-C expression
US20040120950A1 (en) *	2002-12-20	2004-06-24	Kari Alitalo	Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20040248796A1 (en) *	2003-02-04	2004-12-09	Kari Alitalo	VEGF-B and PDGF modulation of stem cells
EP1635860A2 (de) *	2003-06-12	2006-03-22	Ludwig Institute For Cancer Research	Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
WO2005016963A2 (en) *	2003-06-12	2005-02-24	Ludwig Institute For Cancer Research	Heparin binding veger-3 ligands
US6990436B1 (en) *	2003-11-28	2006-01-24	The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration	Computing frequency by using generalized zero-crossing applied to intrinsic mode functions
WO2005087177A2 (en) *	2004-03-05	2005-09-22	Ludwig Institute For Cancer Research	Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US9044140B2 (en) *	2004-06-30	2015-06-02	University Of Rochester	Photodynamic therapy with spatially resolved dual spectroscopic monitoring
EP2314614B1 (de)	2005-02-28	2015-11-25	Sangamo BioSciences, Inc.	Anti-angiogene Verfahren und Zusammensetzungen
EP1919944B1 (de)	2005-08-15	2011-03-23	Vegenics Pty Ltd	Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US20070282404A1 (en) *	2006-04-10	2007-12-06	University Of Rochester	Side-firing linear optic array for interstitial optical therapy and monitoring using compact helical geometry
WO2008080052A1 (en) *	2006-12-22	2008-07-03	Genentech, Inc.	Transgenic mice expressing humanized vegf
WO2008096268A2 (en) *	2007-02-07	2008-08-14	Vegenics Limited	Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
WO2008137737A2 (en) *	2007-05-02	2008-11-13	University Of Rochester	Feedback-controlled method for delivering photodynamic therapy and related instrumentation
US8565507B2 (en) *	2008-05-23	2013-10-22	University Of Rochester	Automated placental measurement
US8107710B2 (en)	2008-05-23	2012-01-31	University Of Rochester	Automated placental measurement
WO2010009412A2 (en)	2008-07-18	2010-01-21	University Of Rochester Medical Center	Low-cost device for c-scan photoacoustic imaging
WO2010045421A2 (en) *	2008-10-15	2010-04-22	University Of Rochester	Photoacoustic imaging using a versatile acoustic lens
US20110081056A1 (en) *	2009-10-05	2011-04-07	Salafia Carolyn M	Automated placental measurement
PT2956476T (pt)	2013-02-18	2020-02-21	Vegenics Pty Ltd	Moléculas de ligação e usos destas
EP4121106A1 (de) *	2020-03-20	2023-01-25	Centre National de la Recherche Scientifique (CNRS)	Neue anti-vegfc-antikörper und verwendungen davon

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US5332671A (en) *	1989-05-12	1994-07-26	Genetech, Inc.	Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) *	1989-07-27	1993-06-15	Scios Nova Inc.	DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
RU2128227C1 (ru) *	1989-12-22	1999-03-27	Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова)	Способ активации транскрипционно-молчащего гена
DE69229454T2 (de) *	1991-03-28	2000-01-05	Merck & Co., Inc.	Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
AU664847B2 (en) *	1991-05-15	1995-12-07	Cell Genesys, Inc.	Genomic modifications with homologous DNA targeting
US5326695A (en) *	1992-05-15	1994-07-05	Ludwig Institute For Cancer Research	Platelet derived growth factor agonists
TW402639B (en) *	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US6608182B1 (en) *	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
ES2249762T3 (es) *	1994-03-08	2006-04-01	Human Genome Sciences, Inc.	Factor de crecimiento del endotelio vascular 2.
US5932540A (en) *	1994-03-08	1999-08-03	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
GB9410534D0 (en) *	1994-05-26	1994-07-13	Lynxvale Ltd	Improvements in or relating to growth factor inhibitors
CA2192235C (en) *	1994-06-09	2011-02-15	Kari Alitalo	Flt4 receptor tyrosine kinase and its use in diagnosis and therapy
US5814464A (en) *	1994-10-07	1998-09-29	Regeneron Pharma	Nucleic acids encoding TIE-2 ligand-2
US6645933B1 (en) *	1995-08-01	2003-11-11	Helsinki University Licensing Ltd. Oy	Receptor ligand VEGF-C
US5607918A (en) *	1995-03-01	1997-03-04	Ludwig Institute For Cancer Research	Vascular endothelial growth factor-B and DNA coding therefor
IL117645A (en) *	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
WO1996039421A1 (en) *	1995-06-06	1996-12-12	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 3
DE69628652T3 (de) *	1995-09-08	2012-05-03	Genentech, Inc.	Vegf-verwandtes protein
WO1997017442A1 (en) *	1995-11-08	1997-05-15	Immunex Corporation	Flk-1 binding protein

1997
- 1997-02-05 US US08/795,430 patent/US6130071A/en not_active Expired - Lifetime
1998
- 1998-02-02 CA CA2279554A patent/CA2279554C/en not_active Expired - Fee Related
- 1998-02-02 AU AU62624/98A patent/AU748369C/en not_active Ceased
- 1998-02-02 JP JP53317898A patent/JP4524340B2/ja not_active Expired - Fee Related
- 1998-02-02 AT AT98904842T patent/ATE391778T1/de not_active IP Right Cessation
- 1998-02-02 DE DE69839340T patent/DE69839340T2/de not_active Expired - Lifetime
- 1998-02-02 EP EP98904842A patent/EP0972028B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2001523951A (ja)	2001-11-27
EP0972028B1 (de)	2008-04-09
US6130071A (en)	2000-10-10
EP0972028A1 (de)	2000-01-19
JP4524340B2 (ja)	2010-08-18
DE69839340D1 (de)	2008-05-21
CA2279554A1 (en)	1998-08-06
AU748369C (en)	2003-03-20
AU6262498A (en)	1998-08-25
DE69839340T2 (de)	2009-04-09
AU748369B2 (en)	2002-06-06
CA2279554C (en)	2012-09-18

Legal Events

Date	Code	Title	Description
2008-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE391778T1 (de)	2008-04-15	Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen
ATE434034T1 (de)	2009-07-15	Rekombinanter vasculärer endothelzellen wachstumsfaktor d (vegf-d)
NO20040154L (no)	1998-10-07	Farmasoytisk blanding omfattende human-antistoffer som binder TNF<alfa>, samt anvendelser derav
DE69834027D1 (de)	2006-05-18	Tumor-nekrose-faktor rezeptor 5
ATE365796T1 (de)	2007-07-15	Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
NO973933L (no)	1997-09-01	Vaskulær endotelvekstfaktor B
ATE404583T1 (de)	2008-08-15	Funktionelle antagonisten von hedgehog-aktivität
NO930011L (no)	1993-02-22	Tilfeldig boi-oligomer bibilotek og fremgangsmaate for syntese og anvendelse derav
DK1012274T4 (da)	2011-07-25	Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
DE69535641D1 (de)	2007-12-27	Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
DK1005540T3 (da)	2004-10-18	IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EP0653940A4 (de)	1997-02-26	Glialmitogene faktoren, ihre herstellung und verwendung.
DK0922102T3 (da)	2010-08-16	Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
ATE259377T1 (de)	2004-02-15	An den zelloberflächenrezeptor hek bindendes cytokin
NO971341D0 (no)	1997-03-21	Promoter for reseptor tyrosinkinase TIE
MXPA02008239A (es)	2004-08-12	Gen humano de la esquizofrenia.
PT877803E (pt)	2005-11-30	Receptor da proteina ob e composicoes e metodos afins
MX9702789A (es)	1997-07-31	Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
WO1994026891A3 (en)	1995-01-19	Purified mammalian flt3 ligands and agonists and antagonists thereof
DK1009817T3 (da)	2010-01-18	RTD-receptor
PT1007559E (pt)	2006-05-31	Celulas geneticamente modificadas que expressam as proteinas morfogeneticas do osso
EP0990703A4 (de)	2001-09-12	Neues polypeptid, dafür kodierende dna und deren verwendungen
NZ504025A (en)	2003-04-29	Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease
DK0781344T3 (da)	2006-02-13	Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
DE69734596D1 (de)	2005-12-15	"smoothened" proteine aus wirbeltieren